LGND 241018 100.00C (LGND241018C100000) Stock Options, News & Quotes

7.20
+3.11+76.04%

15min DelayClose Oct 4 16:00 ET

7.20High7.20Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Moomoo AI

Feb 29 09:33

Ligand Pharmaceuticals' key financial indicators are inconsistent, raising questions about the sustainability of its current share price momentum. The company's low ROE and declining net income, along with shrinking earnings despite retaining all profits, suggest potential issues with its business operations or capital allocation.

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Moomoo AI

Jan 25 06:30

Insider selling at Ligand Pharmaceuticals, particularly at current share price, raises caution. Modest insider ownership indicates some alignment with shareholders, but lack of recent insider transactions doesn't raise immediate concerns.

Several Ligand Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal

Moomoo AI

Dec 20, 2023 08:52

Ligand Pharmaceuticals' high P/E ratio may be plausible with outstanding growth. Its promising future earnings outlook may prevent investors from selling stocks. Unless earnings decline, the current P/E ratio could support the share price.

Investors Appear Satisfied With Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Prospects

Moomoo AI

Oct 18, 2023 07:50

Soticlestat's potential in treating Lennox-Gastaut and Dravet syndromes is backed by Ovid and Ligand's deal. Ligand sees the deal aligning with its strategy of investing in solutions answering high unmet needs, promising high-margin growth for its investors.

Press Release: Ovid Therapeutics and Ligand Pharmaceuticals Enter Into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway Into 2026

Weight-loss drugmakers report strong earnings: Boon or bane?